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Osteoporosis pseudoglioma syndrome (OPPG) is a rare autosomal recessive condition of congenital blindness 
and severe childhood osteoporosis with skeletal fragility, caused by loss-of-function mutations in the LRP5 
(Low-density lipoprotein receptor-related protein 5) gene. We report the first case of atypical (subtrochanteric) 
femoral fracture (AFF) in OPPG, occurring in a 38 year old man within the context of relatively low bone 
turnover and trabecular osteoporosis on bone histology. We identify two novel LRP5 mutations: R752W is 
associated with low bone mass density (BMD), as demonstrated by the heterozygous carriage identified in his 
57 year old mother; however, the combination of this R752W mutation with another novel W79R mutation, 
causes a severe case of compound heterozygous OPPG. We undertake three-dimensional homology modelling 
of the four extracellular YWTD β-propeller/EGF-like domains (E1-E4) of LRP5, and show that both novel 
mutations destabilise the -propeller domains that are critical for protein and ligand binding to regulate Wnt 
signalling and osteoblast function. Whilst AFFs have been reported in other rare bone diseases, this is the first 
in a genetic condition of primary osteoblast dysfunction. The relatively low bone turnover observed, and 










Atypical femoral fractures (AFF) have been reported in patients taking anti-resorptive therapy, particularly for 
prolonged durations, although they can occur in bisphosphonate-naive individuals. The pathogenesis of AFF 
remains unclear and much anxiety exists regarding the association between commonly used osteoporosis 
treatments and AFF(1). Studying rare genetic diseases, such as LRP5 disorders, can offer insights into the 
understanding of more common diseases. 
Loss-of-function LRP5 mutations cause osteoporosis pseudoglioma syndrome(2) (OPPG, OMIM:259770), a rare 
autosomal recessive disorder, characterised by congenital or juvenile-onset blindness, severe juvenile-onset 
osteoporosis(3;4), skeletal fragility(5) and occasionally learning difficulties(6). Approximately 70 cases have been 
reported worldwide(6-10). Ocular abnormalities are detected at birth or in the first few years of life. Short stature 
and bone deformities can develop. Biochemical markers of bone resorption and formation are usually 
normal(5;11). Heterozygous carriers often have decreased bone mass but normal eye sight(2;12;13). Activating 
LRP5 mutations confer the opposing phenotype of high bone mass and fracture resistance (HBM, 
OMIM:601884)(14-17).  
LRP5 is a cell-surface receptor which activates the canonical Wnt/-catenin pathway, regulating osteoblastic 
bone formation(10). The LRP5  protein carries an extracellular domain composed of four -propellers and EGF 
motifs and three LDL-receptor domains, a 23-amino acid membrane-spanning segment and an intracellular 
domain(18). Most loss-of-function mutations contributing to OPPG, including homozygous mutations and 
compound heterozygotes, have been described in the highly conserved second -propeller binding domain of 
the LRP5 protein(19). 
Here we describe the first report of an atypical femoral fracture in a case of OPPG, explained by two novel 
missense LRP5 mutations, and discuss the insights this provides. We further developed and validated LRP5 
protein models showing both heterozygous mutations destabilise their respective LRP5 β-propellers; domains 




We report the case of a 40-year old white European man with OPPG. Congenital blindness was diagnosed at 6 
months of age and osteoporosis aged 11 following his first 3 fractures (wrist aged 7, wrist aged 8, humerus aged 
10). He suffered a low trauma fracture of the femur aged 16 leading to an abnormal gait due to unequal leg 
length. A bone biopsy at this time showed normal cortical thickness, normal mineralization, but severe 
trabecular osteoporosis. He sustained further fractures of the humerus aged 23 and then a unilateral atypical 
subtrochanteric femoral fracture aged 38 years when he slipped off a low curb whilst walking (Figure 1); he had 
received no anti-resorptive therapy before this time and had no prodromal pain. The fracture was managed by 
open reduction and internal fixation with a plate and screws (Supplemental figure S1). 
Although a non-smoker, his alcohol consumption is high averaging 64 units per week; diet otherwise normal 
with unlimited exercise tolerance. He has no children. Extensive corneal scarring and iris hypoplasia in his right 
eye now limits his visual perception to light and dark. His left eye vision is severely limited by a persistent 
embryonic hyaloid amblyopia with convergent squint, nystagmus, raised intraocular pressure and cataract. On 
examination, he was obese (height 163cm, weight 105kg, BMI 39.5kg/cm2, arm span 184cm), with both mild 
kyphosis and pectus carinatum, a mild leg length deficit, but no signs of joint disease. He had normal nails, 
sclera, hearing, dentition and cardiovascular and neurological examinations. Serum calcium, phosphate, 
alkaline phosphatase and fasting glucose were all normal, biochemistry showed no evidence of renal, 
inflammatory or endocrine disease. 25(OH) vitamin D level was 43 nmol/L; bone turnover markers were low 
[serum C-terminal collagen crosslinks (CTX) 0.02 g/L and N-terminal procollagen (P1NP) 24 g/L] before 
anti-resorptive treatment. Dual Energy X-ray Absorptiometry (DXA) scanning measured L1-L4 T-score -3.1, 
with femoral neck T-score -1.3 (Supplemental Figure S2). He received 9 months of oral alendronate with 
supplementary calcium and vitamin D after his atypical femoral fracture (aged 38), but this was discontinued 
after specialist review.  
Our index case reported a 36-year old sister with very similar phenotype (Supplemental Figure S3): congenital 
blindness, early onset kyphosis, short stature, and four fractures to date, but no DNA sample was available. In 
contrast, their 57-year old mother, without ophthalmological disease, had only experienced a greenstick forearm 
fracture aged 8. After menarche at 13 and menopause at 53 years, she developed diet-controlled type II diabetes 
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mellitus. She consumes 30 units alcohol/week and smokes 30 cigarettes/day. Her DXA L1-L4 T-score was -2.7 
and femoral neck T-score -1.7 (Supplemental Figure S4); FRAX assessment recommend lifestyle advice. There 
are no other cases of OPPG in her family. Our index case reported his 60-year old father (Supplemental Figure 
S3) to have no eye disease but, although fracture-free, he has developed a kyphosis with height loss. He has two 
further offspring by a second relationship; none show an OPPG phenotype. There was no history of 
consanguinity. 
The family has never previously sought genetic testing as the mother had ascribed her offspring’s phenotypes to 
her use of the antiemetic Debendox (dicuclomine-doxylamine-pyridoxine) during pregnancy, despite a series of 
epidemiological studies in the late 1970s finding no evidence of teratogenicity(20-22). 
METHODS 
LRP5 Sequencing 
Genomic DNA from blood was obtained using QIAamp DNA blood extraction kit (Qiagen, GmbH, Hilden, 
Germany) following manufacturer’s indications.  Written informed consent was obtained from the index case 
and his mother. Research complied with the World Medical Association Declaration of Helsinki-Ethical 
Principles for Medical Research Involving Human Subjects. We amplified by PCR and directly sequenced, 
using Sanger methodology, all 23 exons of human LRP5 (RefSeq NM_002335) as well as the relevant exon-
intron boundaries. Primers for PCR and sequencing were designed using Primer3 v4.0.0 software(23;24) 
(Supplemental Table S1). Mutations found were confirmed on two independent PCR products. 
In silico analysis of novel LRP5 mutations 
Novel missense LRP5 mutations were analysed using PolyPhen-2(25), SIFT(26), Pmut(27), PANTHER(28), Align-
GVGD(29), and MutationTaster(30). Modelling of the four extracellular YWTD β-propeller/EGF-like domains of 
human LRP5 (E1-E4) was undertaken using Modeller 9v12(31;32) based upon highly similar crystal structure 
template domain-fragments of LRP6 – E1-E2 (PDB ID: 4DG6) and E3-E4 (PDB ID: 4A0P). The LRP5 E1-E2 
and E3-E4 domains share ~76% and ~72% sequence identity (~86% sequence similarity in both cases) with the 
template LRP6 sequences, respectively. The target-template alignment was based upon multiple sequence 
alignment among related LRP5/6 protein sequences using ClustalX(33). Fifty models were generated using 
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Modeller 9v12, and the one with the lowest objective function score selected as the representative model in 
each case. The models were assessed using PROCHECK(34), WHAT IF(35;36) and MetaMQAPII(37). Details 
about the protein model quality assessment are provided in the Supplementary Table S2. FoldX(38;39) was used 
to estimate the free energy difference (stability change, expressed as ΔΔG) upon mutagenesis from wild-type 
for the mutations.  
RESULTS 
PCR amplification and sequencing of LRP5 revealed two novel missense mutations in our OPPG index case. 
We found in both the index case and his mother, a novel heterozygous c.2254C>T (p.R752W) mutation 
(Supplemental Figure S5A, S5B). Our OPPG index case also carried a second novel heterozygous missense 
mutation, c.235T>C (p.W79R) (Supplemental Figure S5C). In silico bioinformatic analysis suggested both 
mutations are deleterious (Supplemental Table S3). Both substituted amino acids are evolutionarily strictly 
conserved among LRP5 orthologues and also among related LRP4 and LRP6 sequences(40) (Supplemental 
Figures S6 and S7). 
In order to further assess potential impact of the mutations on the structure and function of LRP5, we created 
and validated three-dimensional (3-D) homology models for the four extracellular YWTD β-propeller/EGF-like 
domains (E1-E4) of LRP5. Mutation W79R is located in the second β-strand of blade 2 in the E1 domain, 
within the highly conserved “YWTD” signature motif, and is completely buried in the core of the β-propeller 
(Figure 2A). Protein stability calculations using FoldX on the 3-D model of LRP5-E1-E2 predict this mutation 
to severely destabilise structure (mean ΔΔG = ~5 kcal/mol), based upon previously published studies(39;41;42) 
(ΔΔG >1.6 kcal/mol infers severely reduced structural stability). The R752W mutation, located in blade 3 of E3 
domain, near the interface with E4 (Figure 2B), is also predicted to destabilise structure, albeit to a lesser extent 
(mean ΔΔG = ~2 kcal/mol). 
DISCUSSION 
To our knowledge, this is the first report of an atypical subtrochanteric femoral fracture occurring in a case of 
OPPG. Furthermore, we have identified two novel missense LRP5 mutations explaining this compound 
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heterozygous case of OPPG, supported by 3-D protein models showing significant deleterious structural 
consequences to the LRP5 protein. 
This AFF occurred within the context of relatively low bone turnover, impaired Wnt signalling due to predicted 
destabilisation of LRP5, and trabecular osteoporosis with normal mineralization on histology, which implicates 
impaired bone remodelling in the pathogenesis of AFF. Given our knowledge of LRP5 function, we 
hypothesize that this relatively low bone turnover state in adult OPPG may be chronic. Prolonged suppression 
of bone turnover with bisphosphonates, used to treat osteoporosis, has also been associated with AFF(1). 
The underlying pathogenesis of AFF remains unclear. AFFs may represent a stress or insufficiency fracture, 
developing from accumulated cortical microcracks in response to repetitive loading, repair of which is 
hampered if bone remodelling is impaired(1). However, in contrast to stress fractures, AFFs usually start from 
the lateral (rather than medial) cortex, and fracture with a smooth transverse (rather than oblique) edge, 
suggestive of ‘brittle bone’, as seen in Figure 1. Femoral alignment, varus neck-shaft angle and shorter hip-axis 
length have been associated with AFF (43;44), with the initial cortical lesions occurring at the lateral femoral site 
under greatest tensile load (45). Whether our index cases’ mild leg-length deficit altered his lower limb 
biomechanics to increase tensile stress over the left lateral femur, predisposing to AFF, is unclear.  
AFFs are thought to develop from a cortical defect. Earlier our index cases’ bone biopsy had shown normal 
cortical thickness, but with trabecular osteoporosis. Clinical vertebral fractures have been reported more 
commonly in a handful of AFF cases(46). Whether a weakened trabecular scaffold within the femoral 
subtrochanteric region predisposes to cortical microcrack propagation is not known. Further lowering bone 
turnover by bisphosphonate therapy for OPPG, proposed by some in earlier case reports(11;47), is inadvisable in 
our case, where arguably anabolic therapy would be the most appropriate therapeutic intervention. 
AFFs have been reported in other rare bone diseases causing (i) impaired bone resorption due to osteoclast 
dysfunction with increased bone density e.g. pycnodysostosis(48), autosomal dominant type II osteopetrosis(49-51) 
(2 of 3 osteopetrosis cases occurred after high trauma accidents), and (ii) impaired mineralization due to 
hypophosphatasia(52). Until now AFF has never been reported in a genetic condition of primary osteoblast 
dysfunction. 
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We have identified two novel missense mutations in LRP5. Mutation R752W, within the E3 domain, is 
predicted to destabilise protein structure; however, the pathological effect is comparatively subtle, conferring 
only low BMD (no eye disease) in our postmenopausal mother who has other risk factors for low BMD, 
consistent with the mean G just above the predicted destabilisation threshold (only ~0.4kcal/mol above the 
1.6kcal/mol threshold). Interestingly, a R752G mutation has been described in familial exudative 
vitreoretinopathy(40); a rare retinal disorder with some cases showing reduced BMD(53). In addition to R752W, 
our index case has a second novel missense mutation; W79R, located within the core of the E1 -propeller 
domain, is predicted to severely destabilise structure because of inappropriate burial of the polar/charged 
Arginine residue within a key conserved structural (YWTD) motif. Since we could not sequence either the 
father (normal vision) or sibling (with the same OPPG phenotype) we could not determine whether this second 
mutation is de novo or paternally inherited. Paternal inheritance is likely given the sibling’s affection status and 
the father’s height loss with kyphosis suggestive of osteoporosis. 
LRP5 regulates bone formation through activation of osteoblastic Wnt/-catenin canonical signalling(54). 
Development of OPPG has been associated with homozygous and compound heterozygous mutations in 
LRP5(2;6). No phenotypic differences have been reported between homozygotes and compound heterozygotes(6). 
Interestingly, common polymorphisms in LRP5 influence BMD in the general population(55-60); the genetic 
architecture of individuals within the general population sustaining AFF is unknown. 
It has been suggested that LRP5 regulates bone mass through duodenal serotonin synthesis(61), although 
subsequent analyses have not all supported this finding(62;63). Furthermore, serotonin levels in high bone mass, 
due to activating LRP5 mutations, have been reported to be normal(64); whether the same holds for OPPG 
remains to be determined. 
In conclusion, we report the first case of atypical femoral fracture in a case of OPPG within the context of 
relatively low bone turnover, trabecular osteoporosis and impaired osteoblast function. The novel mutation 
R752W is associated with low BMD, but the combination of this mutation with another novel W79R mutation, 
causes a severe case of compound heterozygous OPPG, due to destabilisation of the -propellers of the LRP5 
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Figure 1. X-ray showing a left atypical femoral fracture sustained by the index case aged 38. A subtrochanteric, 
transverse, non-comminuted fracture with medial spike is seen. Generalised increases in cortical thickness are 
seen in the diaphyses. 
Figure 2. A) The 3-D model of LRP5 E1-E2 showing location of missense mutation W79R (sphere 
representation) in the second β-strand of blade 2 in the E1 domain. W79 is completely buried within the core of 
the β-propeller and the mutation is predicted to severely destabilise structure. A transparency setting was used 
for the surface representation to show the location of the buried residue on the secondary structure cartoon 
representation. Each of the blades that make up the six-bladed β-propeller structure in E1, and the four β-
strands that make up blade 2 are labelled. B) Side-view of the 3-D model of LRP5 E3-E4 showing missense 
mutation R752W (sphere representation). R752 is located in blade 3 of the E3 domain, near the interface with 
E4.  
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